Browsing Tag
Melanoma
22 posts
Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum
Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact.
Bristol Myers Squibb’s Opdualag fails to meet primary endpoint in Phase 3 trial
Bristol Myers Squibb has announced that its Phase 3 RELATIVITY-098 clinical trial, designed to evaluate Opdualag (nivolumab and…
SciBase expands US reach, advancing early melanoma detection with AI-powered technology
SciBase Holding AB (STO: SCIB), a leader in AI-driven dermatology solutions, has taken a significant step forward in…
The rising impact of Melanoma: Understanding the risks, causes, and advances in treatment
Melanoma, a severe form of skin cancer, originates in melanocytes, the pigment-producing cells responsible for skin color. Known…
Achilles Therapeutics shares skyrocket 32% after massive cost cuts—Is this the turnaround it needs?
Achilles Therapeutics PLC saw its American Depositary Receipts (ADRs) soar by an impressive 32%, reflecting renewed investor optimism…
FDA approves Iovance’s AMTAGVI: A breakthrough in melanoma treatment
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a trailblazer in the field of biotechnology focused on developing novel polyclonal tumor…
Moderna, Merck announce promising results for mRNA-4157 and Keytruda in melanoma
Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada,…
Moderna, Merck get FDA breakthrough status for mRNA-4157/V940, KEYTRUDA combo in melanoma
Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung…
ImmVira wraps up first dosing for MVR-T3011 in US and China
ImmVira said that it has wrapped up the first dosing of its oncolytic virus product – MVR-T3011 intratumoral…
OncoSec Medical begins phase 2 trial for TAVO and OPDIVO combination in melanoma treatment
OncoSec Medical, a US-based biotechnology company, has officially dosed the first patient in its phase 2 clinical trial,…